Effect of Dilatation and Curettage on the Endometrial Receptivity

NCT ID: NCT03485235

Last Updated: 2020-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

160 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-03-31

Study Completion Date

2019-12-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Effect of dilatation and curettage on the endometrial receptivity and pregnancy outcome in patients with recurrent implantation failure

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Embryo Implantation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

D&C

Group Type EXPERIMENTAL

D&C

Intervention Type PROCEDURE

Dilatation and curettage

ICSI

Intervention Type PROCEDURE

Intra Cytoplasmic Sperm Injection

No D&C

Group Type OTHER

ICSI

Intervention Type PROCEDURE

Intra Cytoplasmic Sperm Injection

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

D&C

Dilatation and curettage

Intervention Type PROCEDURE

ICSI

Intra Cytoplasmic Sperm Injection

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. All the patients had at least 3 failed trials of IVF-ET with day 5 fresh blastocyst transferred
2. At least 10 high-grade embryos were obtained in the previous trials
3. Level of AMH more than or equal 1.1 ng/ml.
4. Age: Less than or equal to 35 years

Exclusion Criteria

1. Patients with uterine pathology e.g. myoma , Asherman syndrome, Septum ,adenomyosis
2. Hydrosalpinx
3. Endometriosis
4. patients with diagnosed autoimmune diseases affecting pregnancy e.g. S.L.E.
Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Mohamed S Sweed, MD

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University Maternity Hospital

Cairo, , Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

AS1764

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Uterine Peristalsis in IVF
NCT06036459 NOT_YET_RECRUITING